Kiniksa Pharmaceuticals International, plc (KNSA) › Cash & EquivalentsKiniksa Pharmaceuticals International, plc (KNSA) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2017: $45.55M2018: $71.98M2019: $46.93M2020: $114.04M2021: $122.47M2022: $122.72M2023: $107.95M2024: $183.58M2025: $165.60M$165.60M2017Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$165.60M-9.8%2024$183.58M+70.1%2023$107.95M-12.0%2022$122.72M+0.2%2021$122.47M+7.4%2020$114.04M+143.0%2019$46.93M-34.8%2018$71.98M+58.0%2017$45.55M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share